EVALUATION SURVEY 39 ERTC
Your feedback is important! Please share your thoughts on the 39th ERTC Workshop. Your advice helps inform our future workshops.
In what capacity did you attend the 39th ERTC workshop?
*
Pharmaceutical & Biotech Representative
Health Industry Syndicates
Policy Makers/ HTA/ Reimbursement authorities/ Regulatory Experts
Patients/ Patient Representatives
Academics/ Healthcare Professionals/ Researchers
EURORDIS Members of the Board/Staff
Other
What country are you based in?
*
Overall, how satisfied or dissatisfied are you with the 39th ERTC Workshop?
Very satisfied
Satisfied
Somewhat satisfied
Neither satisfied nor dissatisfied
Somewhat dissatisfied
Dissatisfied
Very dissatisfied
To what extent do you agree that speakers and moderators facilitated learning exchanges?
Strongly agree
Agree
Neither agree nor disagree
Disagree
Strongly disagree
Which break-out session did you attend in the morning?
*
Accelerating clinical trials to ensure research innovations translate into tangible health benefits
Capitalising on public-private investments to boost patient-led rare disease research
I did not attend any break-out sessions
Back
Next
To what extent did the session provide relevant insights into innovative ways to improve and optimise clinical trials in Europe?
*
Very much
Much
Some
Little
Very little
How much involvement does your company have in public-private collaborations?
*
Very much
Much
Some
Little
Very little
How likely is your company to consider solutions that are more conducive to improving clinical trials in Europe for rare disease patients
*
Very likely
Likely
Neither likely nor unlikely
Not likely
Very unlikely
How likely is your company to consider collaborative opportunities to help design policy solutions and de-risk investment in rare diseases
*
Very likely
Likely
Neither likely nor unlikely
Not likely
Very unlikely
Not at this time
To what extent do you agree that speakers and moderators facilitated learning exchanges?
Strongly agree
Agree
Neither agree nor disagree
Disagree
Strongly disagree
To what extent do you agree that speakers and moderators facilitated learning exchanges?
Strongly agree
Agree
Neither agree nor disagree
Disagree
Strongly disagree
What is your main takeaway from this session (optional)
What is your main takeaway from this session (optional)
Which break-out session did you attend in the afternoon?
*
‘Bridging the gap’: strengthening European healthcare systems for equitable patient access
Advancing equity in newborn screening
I did not attend any break-out sessions
To what extent did the session provide relevant insights into innovative ways to improve patient access and strengthen European healthcare systems?
*
Very much
Much
Some
Little
Very little
Has the breakout session helped to clarify the role of industry in making NBS more accessible to people living with a rare condition
*
Very much
Much
Some
Little
Very little
How likely are you to continue advocating for increased readiness in healthcare systems to maximise sustainable access to therapies
*
Very likely
Likely
Neither likely nor unlikely
Not likely
Very unlikely
How likely are you to advocate for genomic newborn screening to support investment into new therapies for rare conditions
*
Very likely
Likely
Neither likely nor unlikely
Not likely
Very unlikely
To what extent do you agree that speakers and moderators facilitated learning exchanges?
Strongly agree
Agree
Neither agree nor disagree
Disagree
Strongly disagree
To what extent do you agree that speakers and moderators facilitated learning exchanges?
Strongly agree
Agree
Neither agree nor disagree
Disagree
Strongly disagree
What is your main takeaway from this session (optional)
What is your main takeaway from this session (optional)
Back
Next
Please rate the following aspects of the workshop:
Clarity of content:
Worst
1
2
3
4
Best
5
1 is Worst, 5 is Best
Capacity building and knowledge acquisition:
Worst
1
2
3
4
Best
5
1 is Worst, 5 is Best
Networking:
Worst
1
2
3
4
Best
5
1 is Worst, 5 is Best
Interactivity and sharing information/ opinions:
Worst
1
2
3
4
Best
5
1 is Worst, 5 is Best
Accessibility measures in place:
Worst
1
2
3
4
Best
5
1 is Worst, 5 is Best
Please let us know if you have any additional comments or suggestions for future ERTC workshop topics
If you would like to, please provide us with your full name and company/ organisation/ institution
Submit
Should be Empty: